Related Insights

Article

Can Chinese Phase I data from the West accelerate China drug development?

Mar 17, 2021

Article

Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021

Blog

A hybrid model supports globally diverse site participation for a retrospective cancer study

Jul 24, 2023

Podcast

Enabling Successful Sites, episode 1: Site Feasibility and Study Start-up Challenges

May 10, 2024

Blog

Highlights from ISMPP Asia Pacific Meeting 2021

Sep 20, 2021

Blog

New Real World Evidence leader in Asia/Pacific returns to Parexel with lessons learned from China adventure

Jan 13, 2023

Blog

Preparing for a new era in European Market Access

Jul 22, 2022

Blog

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022

Article

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022

Article

How emerging biotechs can enter the Chinese market and prosper

Jan 18, 2022

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Article

Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?

Aug 6, 2021